SWEDISH ORPHAN BIOVITRUM
- Country
- ๐ซ๐ทFrance
- Ownership
- -
- Established
- 2010-01-01
- Employees
- -
- Market Cap
- $10.7B
- Website
- http://www.sobi.com/
An International Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B
- First Posted Date
- 2019-04-03
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 151
- Registration Number
- NCT03901755
- Locations
- ๐ฌ๐ง
Swedish Orphan Biovitrum Research Site, Oxford, United Kingdom
๐ฌ๐ทSwedish Orphan Biovitrum Research Site (Haemophilia Center Aghia Sophia Children's Hospital), Athens, Greece
๐ธ๐ฆSwedish Orphan Biovitrum Research Site (King Faisal Hospital pediatric), Riyadh, Saudi Arabia
A Study to Assess the Safety, Tolerability, and Efficacy of Long-term SOBI003 Treatment in Pediatric MPS IIIA Patients
- First Posted Date
- 2019-01-22
- Last Posted Date
- 2022-02-25
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 6
- Registration Number
- NCT03811028
- Locations
- ๐บ๐ธ
Childrenยดs Hospital and research center, Oakland, California, United States
๐น๐ทGazi University Hospital, Ankara, Turkey
๐บ๐ธUniversity of North Carolina hospitals, Chapel Hill, North Carolina, United States
A Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B in France
- First Posted Date
- 2018-08-31
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 91
- Registration Number
- NCT03655340
- Locations
- ๐ซ๐ท
Swedish Orphan Biovitrum Research Site, Toulouse, France
๐ซ๐ทSwedish Orphan Biovitrum Research Site (CHU de Bordeaux), Bordeaux, France
๐ซ๐ทSwedish Orphan Biovitrum research site, Strasbourg, France
A Study to Assess the Safety and Tolerability of SOBI003 in Pediatric MPS IIIA Patients
- First Posted Date
- 2018-02-06
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 6
- Registration Number
- NCT03423186
- Locations
- ๐บ๐ธ
Childrens's Hospital and Research Center, Oakland, California, United States
๐บ๐ธUniversity of North Carolina Hospitals, Chapel Hill, North Carolina, United States
๐น๐ทGazi University Hospital, Ankara, Turkey
Study to Assess the Efficacy and Safety of Emapalumab in Primary Haemophagocytic Lymphohistiocytosis
- First Posted Date
- 2017-10-18
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 35
- Registration Number
- NCT03312751
- Locations
- ๐บ๐ธ
Texas Children's Hospital - Feigin Center, Houston, Texas, United States
๐บ๐ธCincinnati Children's Hospital, Cincinnati, Ohio, United States
๐บ๐ธSeattle Children's Hospital, Seattle, Washington, United States
A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)
- Conditions
- Arthritis, JuvenileLymphohistiocytosis, HemophagocyticAdult Onset Still DiseaseMacrophage Activation Syndrome
- Interventions
- First Posted Date
- 2017-10-17
- Last Posted Date
- 2022-05-17
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 14
- Registration Number
- NCT03311854
- Locations
- ๐ฎ๐น
IRCCS Ospedale Pediatrico, Bambino Gesรน, Rome, Italy
๐ฌ๐งGreat Ormond Street Hospital for Children, London, United Kingdom
๐ช๐ธHospital Sant Joan de Deu, Barcelona, Spain
Management of Health-Related QoL Impairment, Including Pain, Depression and Anxiety, in People With Haemophilia A and B
- Conditions
- Haemophilia AHaemophilia B
- First Posted Date
- 2017-09-08
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 2300
- Registration Number
- NCT03276130
- Locations
- ๐ธ๐ช
Swedish Orphan Biovitrum Research Site, Stockholm, Sweden
A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Still's Disease (SJIA and AOSD)
- Conditions
- Still's Disease, Adult-OnsetStill's Disease, Juvenile-Onset
- Interventions
- Biological: anakinraDrug: Placebo
- First Posted Date
- 2017-08-29
- Last Posted Date
- 2021-06-30
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 13
- Registration Number
- NCT03265132
- Locations
- ๐บ๐ธ
MetroHealth System, Cleveland, Ohio, United States
๐บ๐ธChildren's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
๐บ๐ธUniversity of Vermont Medical Center, Burlington, Vermont, United States
A Phase 3 Study of Pacritinib in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
- Conditions
- Post-essential Thrombocythemia MyelofibrosisPost-polycythemia Vera MyelofibrosisPrimary Myelofibrosis
- Interventions
- Drug: Physician's Choice medications
- First Posted Date
- 2017-05-24
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 399
- Registration Number
- NCT03165734
- Locations
- ๐ฎ๐น
University Polyclinic Foundation "Agostino Gemelli", Rome, Italy
๐ฎ๐นCity of Health and Science of Turin, Turin, Italy
๐ฎ๐นSanta Maria della Misericordia University Hospital of Udine, Udine, Italy
A Study to Investigate the Potential Influence of Nitisinone on the Metabolism and the Transport of Other Drugs in Healthy Volunteers
- Conditions
- Drug Drug Interaction
- Interventions
- First Posted Date
- 2017-04-06
- Last Posted Date
- 2017-08-10
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 36
- Registration Number
- NCT03103568
- Locations
- ๐ฉ๐ช
PAREXEL EPCU Berlin, Berlin, Germany